Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Not applicableStudy completedNCT04887519
What this trial is testing

Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Takeda 39
Large-scale testing (Phase 3)UnknownNCT04632758
What this trial is testing

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 292
Large-scale testing (Phase 3)Active Not RecruitingNCT03456076
What this trial is testing

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 257
Testing effectiveness (Phase 2)Looking for participantsNCT05713006
What this trial is testing

Alectinib Pharmacokinetic in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIIBALK Gene Mutation
Instituto Nacional de Cancerologia de Mexico 45
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Large-scale testing (Phase 3)Study completedNCT02075840
What this trial is testing

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 303
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Early research (Phase 1)Looking for participantsNCT07784959
What this trial is testing

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Who this might be right for
ALK PositiveALK Positive Non-small Cell Lung CancerNSCLC+1 more
Nuvectis Pharma, Inc. 54
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Not applicableNot Yet RecruitingNCT06736561
What this trial is testing

Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Who this might be right for
ALK PositiveEnsartinibNSCLC+1 more
Harbin Medical University 100
Early research (Phase 1)Looking for participantsNCT06225427
What this trial is testing

Gilteritinib for the Treatment of ALK NSCLC

Who this might be right for
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
University of Michigan Rogel Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT05241028
What this trial is testing

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Hebei Medical University Fourth Hospital 80
Not applicableStudy completedNCT04351334
What this trial is testing

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Who this might be right for
Non-Small-Cell Lung Carcinoma
Pfizer 161
Testing effectiveness (Phase 2)Study completedNCT02336451
What this trial is testing

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
Novartis Pharmaceuticals 156
Not applicableStudy completedNCT04947683
What this trial is testing

Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Latin American Cooperative Oncology Group 101
Early research (Phase 1)Ended earlyNCT02511184
What this trial is testing

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Who this might be right for
ALK-positive Advanced NSCLC
Pfizer 9
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Not applicableEnrolling By InvitationNCT06846736
What this trial is testing

ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study

Who this might be right for
Alk-positive Non-Small Cell Lung CancerALK-inhibitor Treated
Sheba Medical Center 200
Not applicableUnknownNCT05132218
What this trial is testing

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveNSCLC Stage IIIBNSCLC Stage IV
Peking University Cancer Hospital & Institute 180
Next Page